Ozempic (semaglutide) and Wegovy (semaglutide) are two medications that contain the same active ingredient, semaglutide, but have different indications, dosages, and uses:
- Indication:
– Ozempic: Type 2 diabetes treatment
– Wegovy: Weight management in adults with obesity or overweight - Dosage:
– Ozempic: 0.5 mg or 1.0 mg once weekly
– Wegovy: 2.25 mg once weekly (higher dose than Ozempic) - Use:
– Ozempic: Improves glycemic control, reduces HbA1c, and has a secondary benefit of weight loss
– Wegovy: Primarily used for weight loss, with a secondary benefit of improving glycemic control - Approval:
– Ozempic: FDA-approved for type 2 diabetes in 2017
– Wegovy: FDA-approved for weight management in 2021 - Labeling:
– Ozempic: Labeled for type 2 diabetes treatment, with a warning about increased risk of pancreatitis and thyroid C-cell tumors
– Wegovy: Labeled for weight management, with a warning about increased risk of pancreatitis, thyroid C-cell tumors, and acute kidney injury
In summary, while both medications contain semaglutide, Ozempic is used for type 2 diabetes treatment, and Wegovy is used for weight management in adults with obesity or overweight. Consult your healthcare provider to determine the appropriate medication and dosage for your specific needs.